View/ Open
Morgan_et_al_Oncotarget.pdf (1.039Mb)
Download
Publication date
2017-03-07Rights
© 2017 Morgan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
2017-02-23
Metadata
Show full item recordAbstract
The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also dysregulated in a wide range of solid and haematological malignancies and have a predominantly pro-oncogenic function. A key mode of transcriptional regulation by HOX and PBX proteins is through their interaction as a heterodimer or larger complex that enhances their binding affinity and specificity for DNA, and there is growing evidence that this interaction is a potential therapeutic target in malignancies that include prostate, breast, renal, ovarian and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its application in precision medicine.Version
Published versionCitation
Morgan R, El-Tanani M, Hunter KD et al (2017) Targeting HOX/PBX dimers in cancer. Oncotarget. 8(19): 32322-32331.Link to Version of Record
https://doi.org/10.18632/oncotarget.15971Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.18632/oncotarget.15971